Support

Support Options

Submit a Support Ticket

 

[Illinois] BioNanotechnology Seminar Series Spring 2012: CYP17A1: Gatekeeper to Androgen Biosynthesis

By Michael Gregory

View Resource (HTM)

Licensed according to this deed.

Published on

Abstract


Human Cytochrome P45017A1 (CYP17) catalyzes the 17 alpha-hydroxylation of pregnenolone and progesterone as well as the subsequent 17,20 carbon-carbon lyase chemistry of its hydroxylated products. CYP17 function plays a central role in human steroid hormone biosynthesis, and its activity is absolutely essential for the formation of androgens. Thus, inhibition of CYP17 has recently been exploited in the treatment of androgen dependent malignancies. Through application of nanotechnology and biophysical tools, we have identified novel characteristics of CYP17 chemistry that may guide development of the next generation of mechanism-based inhibitors.

Bio

After spending his adolescence in the Chicago suburbs, Michael Gregory attended DePauw University where he earned a bachelor's degree in biochemistry in 2008. Following graduation, he returned to the Chicago area and joined the R&D division of a major biopharmaceutical company where he assisted development of protein based therapies for the treatment of pulmonary disorders. In 2009, he came to the University of Illinois and is currently a biochemistry graduate student working in the laboratory of Dr. Stephen Sligar. Here he is studying the steroidogenic enzyme Cytochrome P450c17 (CYP17), which catalyzes the first committed step in androgen formation. As a result of CYP17's role as gatekeeper to androgen biosynthesis it is a front line target in the fight against castration-resistant prostate cancer, which proliferates in response to androgen receptor activation. Michael hopes to integrate knowledge gleaned from rigorous biophysical characterization of CYP17 catalysis with emerging diagnostic and nanotechnologies to encourage development of next-generation therapeutics for the treatment of androgen responsive malignancies such as castration-resistant prostate cancer.

From Michael Gregory's M-CNTC page

Cite this work

Researchers should cite this work as follows:

  • Michael Gregory (2013), "[Illinois] BioNanotechnology Seminar Series Spring 2012: CYP17A1: Gatekeeper to Androgen Biosynthesis," https://nanohub.org/resources/18278.

    BibTex | EndNote

Time

Location

1000 MNTL, University of Illinois, Urbana-Champaign, Urbana, IL

Submitter

NanoBio Node, Adeeb Yunus

University of Illinois at Urbana-Champaign

Tags

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.